GI Dysfunctions in Diabetic Gastroenteropathy, Their Relationships With Symptoms, and Effects of a GLP-1 Antagonist
Open accessThe DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index.
Abstract
CONTEXT: Delayed gastric emptying (GE) is common but often asymptomatic in diabetes. The relationship between symptoms, glycemia, and neurohormonal functions, including glucagonlike peptide 1 (GLP-1), are unclear. OBJECTIVES: To assess whether GE disturbances, symptoms during a GE study, and symptoms during enteral lipid infusion explain daily symptoms and whether GLP-1 mediates symptoms during enteral lipid infusion. DESIGN: In this randomized controlled trial, GE, enteral lipid infusion, gastrointestinal (GI) symptoms during these assessments, autonomic functions, glycosylated hemoglobin (HbA1c), and daily GI symptoms (2-week Gastroparesis Cardinal Symptom Index diary) were evaluated. During enteral lipid infusion, participants received the GLP-1 antagonist exendin 9-39 or placebo. SETTING: Single tertiary referral center. PARTICIPANTS: 24 healthy controls and 40 patients with diabetic gastroenteropathy. MAIN OUTCOME MEASURES: GE, symptoms during enteral lipid infusion, and the effect of exendin 9-39 on the latter. RESULTS: In patients, GE was normal (55%), delayed (33%), or rapid (12%). During lipid infusion, GI symptoms tended to be greater (P = 0.06) in patients with diabetes mellitus (DM) than controls; exendin 9-39 did not affect symptoms. The HbA1c was inversely correlated with the mean symptom score during the GE study (r = -0.46, P = 0.003) and lipid infusion (r = -0.47, P < 0.01). GE and symptoms during GE study accounted for 40% and 32%, respectively, of the variance in daily symptom severity and quality of life. CONCLUSIONS: In DM gastroenteropathy, GE and symptoms during a GE study explain daily symptoms. Symptoms during enteral lipid infusion were borderline increased but not reduced by a GLP-1 antagonist.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Likewise, autonomic dysfunctions were associated with symptoms in some (1), but not all, studies (57).”
From Diabetic Gastroparesis. (2019) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Autonomic dysfunctions are correlated with GI dysmotility (56) and cardiovascular vagal dysfunction is associated with delayed GE in some (58, 59), but not all, studies (1).”
From Diabetic Gastroparesis. (2019) · cites this paper as [1]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139
Depression and quality of life in older persons: A review
Sivertsen, H., Bjørkløf, G. H., Engedal, K., Selbæk, G., & Helvik, A.-S. (2015) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000437299 · Cited by 14,152
Martin, C. L., Albers, J. W., Pop-Busui, R., & for the DCCT/EDIC Research Group (2014) · Diabetes Care · doi:10.2337/dc13-2114 · Cited by 499
Relationships of Upper Gastrointestinal Motor and Sensory Function With Glycemic Control
Rayner, C. K., Samsom, M., Jones, K. L., & Horowitz, M. (2001) · Diabetes Care · doi:10.2337/diacare.24.2.371 · Cited by 460
Rentz, A. M., Kahrilas, P., Stanghellini, V., Tack, J., Talley, N. J., De la loge, C., Trudeau, E., Dubois, D., & Revicki, D. A. (2004) · Quality of Life Research · doi:10.1007/s11136-004-9567-x · Cited by 406
Rao, S. S. C., Camilleri, M., Hasler, W. L., Maurer, A. H., Parkman, H. P., Saad, R., Scott, M. S., Simren, M., Soffer, E., & Szarka, L. (2011) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2010.01612.x · Cited by 379
Epidemiology, mechanisms, and management of diabetic gastroparesis
Camilleri, M., Bharucha, A. E., & Farrugia, G. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2010.09.022 · Cited by 287
Schirra, J., Nicolaus, M., Roggel, R., Katschinski, M., Storr, M., Woerle, H. J., & Göke, B. (2006) · Gut · doi:10.1136/gut.2004.059741 · Cited by 277
Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans
Schirra, J., Sturm, K., Leicht, P., Arnold, R., Göke, B., & Katschinski, M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1349 · Cited by 265
Bharucha, A. E., Kudva, Y. C., & Prichard, D. O. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00161 · Cited by 252
Cited by
Bharucha, A. E., Kudva, Y. C., & Prichard, D. O. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00161 · Cited by 252
Mashayekhi, M., Nian, H., Mayfield, D., Devin, J. K., Gamboa, J. L., Yu, C., Silver, H. J., Niswender, K. D., Luther, J. M., & Brown, N. J. (2023) · Diabetes · doi:10.2337/db23-0356 · Cited by 83
Gastric Sensory and Motor Functions and Energy Intake in Health and Obesity—Therapeutic Implications
Cifuentes, L., Camilleri, M., & Acosta, A. (2021) · Nutrients · doi:10.3390/nu13041158 · Cited by 57
Exendin(9‐39) NH 2 : Recommendations for clinical use based on a systematic literature review
Gasbjerg, L. S., Bari, E. J., Christensen, M., & Knop, F. K. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14507 · Cited by 29
“Obviously, an insulin response (or lack thereof during exendin[9-39]NH2 infusion) strongly depends on the secretory capacity of the beta cells, which ultimately determines the insulinotropic effects of GLP-1.”
BackgroundKuwelker, S., Muthyala, A., O’Connor, M. K., & Bharucha, A. E. (2020) · Neurogastroenterology & Motility · doi:10.1111/nmo.13779 · Cited by 17
“Three 12 (8) 2 (7) Peripheral neuropathya 66 (43) 9 (33)”
Narayanan, S. P., O’Brien, D. R., Sharma, M., Miller, K. N., Adams, P. D., Passos, J. F., Eirin, A., Ördög, T., & Bharucha, A. E. (2021) · JCI Insight · doi:10.1172/jci.insight.143596 · Cited by 17
“Gastric emptying of solids was assessed with a meal (296 kcal; 32% proteins, 35% fats, and 33% carbohydrates) with 2 eggs labeled with technetium Tc (99m technetium pertechnetate) sulfur colloid (1 mCi) and served on 1 slice of bread with milk (8).”
BackgroundMethodKuwelker, S., Prichard, D. O., Bailey, K. R., & Bharucha, A. E. (2021) · Neurogastroenterology & Motility · doi:10.1111/nmo.14154 · Cited by 15
Klinge, M. W., Borghammer, P., Lund, S. A., Fedorova, T. D., Knudsen, K., Haase, A., Christiansen, J. J., & Krogh, K. (2019) · Neurogastroenterology & Motility · doi:10.1111/nmo.13731 · Cited by 13
An Emerging Facet of Diabetes Mellitus: The Nexus of Gastrointestinal Disorders
Modi, S., Gaggatur, N. S., Sange, A. H., Srinivas, N., Sarnaik, M. K., Hassan, M., Gajjela, H., & Sange, I. (2021) · Cureus · doi:10.7759/cureus.18245 · Cited by 14
“However, the definition of gastroparesis is not strictly adherent to a particular set of GI symptoms and is rather complex and inconsistent [19,20].”
BackgroundSmall intestinal bacterial overgrowth in diabetic gastroenteropathy
Varma, R., Chakraborty, S., Burton, D. D., Bailey, K. R., & Bharucha, A. E. (2024) · Neurogastroenterology & Motility · doi:10.1111/nmo.14798 · Cited by 9
“1,3,23,24 The data were summarized as the proportion of patients with severe or intolerable symptoms during the study.”
BackgroundMethodDesai, A., Low, P. A., Camilleri, M., Singer, W., Burton, D. D., Chakraborty, S., & Bharucha, A. E. (2019) · Neurogastroenterology & Motility · doi:10.1111/nmo.13744 · Cited by 8
Epigenetic Alterations Are Associated With Gastric Emptying Disturbances in Diabetes Mellitus
Narayanan, S. P., Lee, J., Bhagwate, A. V., Kuwelker, S., Yan, H., Ördög, T., & Bharucha, A. E. (2020) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000136 · Cited by 6
Fan, M., Tian, J.-L., Chen, T., Zhang, C., Liu, X., Zhao, Z., Zhang, S., & Chen, Y. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i10.2041 · Cited by 6
Deb, B., O’Brien, D. R., Chunawala, Z. S., & Bharucha, A. E. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac038 · Cited by 7
“, retinopathy, peripheral and autonomic neuropathy, and nephropathy) 54 were defined by established criteria (23).”
BackgroundMethodVarma, R., Chakraborty, S., Ramu, S. K., Burton, D. D., Deb, B., Ryks, M. D., Feuerhak, K. J., Bailey, K. R., & Bharucha, A. E. (2024) · Neurogastroenterology & Motility · doi:10.1111/nmo.14857 · Cited by 5
“21,22,31,32”
Rayner, C. K., Jones, K. L., & Horowitz, M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818586-5.00018-1 · Cited by 4
Wang, X. J., O'Connor, M. C., Peck, T., Johnston, G., & Prichard, D. O. (2024) · Neurogastroenterology & Motility · doi:10.1111/nmo.14819 · Cited by 3
Damianos, J., Fredrick, T. W., Jin, M. F., Ospina-Velasquez, L., & Wang, X. J. (2025) · Foregut The Journal of the American Foregut Society · doi:10.1177/26345161251353437 · Cited by 2
“19 Our results at ≥ 10 5 CFU/mL match those of the meta-analysis.”
Tan, R. J. L., Ahuja, A., Shrestha, A., Gallen, G., Stotesbury, B., Cheah, Y., Mustafa, O. G., Whyte, M., Croos, J., Shooshtarian, A. K., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70575 · Cited by 2
“27 Differentiating gastroparesis from functional dyspepsia and other upper GI pathologies can be clinically challenging.”
New models for cancer cachexia and their application to drug discovery
Sato, R., Anker, M. S., Springer, J., & von Haehling, S. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2025.2562020 · Cited by 2
“Similarly, despite evidence of GLP-1 pathway inhibition in preclinical models [116,117], clinical data in healthy and diabetic populations have failed to demonstrate efficacy [118,119].”
Jones, K. L., Marathe, C. S., Wu, T., Rayner, C. K., & Horowitz, M. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-15613-7_27 · Cited by 1
Rayner, C. K., Jones, K. L., & Horowitz, M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-13911-6.00001-3
Akerman, N., Isakov, N. F., Thurm, T., Shnell, M., Sofer, Y., Shibolet, O., & Deutsch, L. (2025) · Therapeutic Advances in Gastrointestinal Endoscopy · doi:10.1177/26317745251359459
Metadata
- Authors
- Chakraborty, S., Halland, M., Burton, D., Desai, A., Neja, B., Low, P., Singer, W., Camilleri, M., Zinsmeister, A. R., & Bharucha, A. E.
- Affiliations
- Mayo Clinic (US)
- Corresponding author
- Bharucha, Adil E
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2018-10-24
- Volume
- 104
- Issue
- 6
- Pages
- 1967-1977
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC6467444
- OpenAlex
- W2898553614
- Cited by
- 23
- References
- 48
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 4 · 2023: 3 · 2022: 1 · 2021: 5 · 2020: 3 · 2019: 3
- FWCI
- 2.62
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (DK68055)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- diabetic gastroparesis, delayed gastric emptying, GLP-1 receptor antagonists, exendin-9-39, gastrointestinal symptoms, HbA1c, autonomic dysfunction, Gastroparesis Cardinal Symptom Index, quality of life, glycemic control
- MeSH terms
- Administration, Oral, Adult, Blood Glucose, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Emulsions, Female, Gastric Emptying, Gastrointestinal Diseases, Glycated Hemoglobin, Humans, Lipids, Male, Middle Aged, Peptide Fragments, Quality of Life, Treatment Outcome, Glucagon-Like Peptide 1, Asymptomatic Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.